Why expertise matters in Neuroscience
More than 85% of CNS trials fail in Phase II or III, often because complex endpoints make true treatment effects hard to detect. Variability across raters, scales, sites, and participants can mask meaningful signals.
Clario brings the CNS expertise required for your trial. Our science-driven eCOA migration and Endpoint Protection Services reduce noise and strengthen signal detection through rater enablement, independent ratings, and proactive analytics.
Clario eCOA Neuroscience experience
1,800+
CNS trials
70k+
sites
500k+
patients
100+
languages
How we help improve and protect your neuroscience trial
Expand each option below to read more about our services.
Comprehensive eCOA platform
Enable remote and site-based ePRO, eClinRO, and ePerfO collection. Access a CNS library of 1,000+ pre-validated, version-controlled assessments for rapid, low-touch configuration for faster deployment.
Science-led eClinRO/ePerfO migration
Every eClinRO and ePerfO is designed and migrated by clinicians, not developers, to ensure scientific accuracy. Our process identifies and prevents common administration and scoring errors through enhanced guidance and consistency checks, delivering up to an 85% reduction in endpoint error rates1
Customized rater training
Structured training tailored to rater experience levels to up-skill sites, alleviate rater shortages, and improve data quality.
Placebo Response Reduction (PRR) training
Equip participants and site staff with validated training modules that address treatment bias and expectation effects. Proven programs such as Accurate Pain/Symptom Reporting (APR/ASR) and Research Subject Responsibilities (RSR) reduce placebo responses and improve signal clarity.
Independent ratings
Reduce bias and variability with remote endpoint assessments conducted by blinded expert clinicians, especially impactful for psychedelic-assisted therapies and other subjective symptom domains.
Independent review
Blinded expert review ensures site based eCOA adhere to standardized administration and scoring practices, consistent with scale requirements, and aligned with rater training.
Study insight analytics
Leverage next-generation monitoring that identifies statistically aberrant signals, focusing remediation where it matters most.
Vocal biomarkers
Incorporate digital measures extracted from speech patterns to sensitively track cognitive and emotional changes associated with disease severity and progression.
Get started today by requesting a capabilities session.
Proven neuroscience expertise
From neurodegenerative diseases to psychiatric conditions and more, Clario’s neuroscience expertise spans a diverse spectrum of disorders, including but not limited to:
Dementias
- Alzheimer’s disease
- Other dementias
Headache disorders
- Migraine
Movement disorders
- Parkinson’s disease
- Ataxia
- Huntington’s disease
Pain management
- Chronic pain
- Neuropathic pain
Psychiatric disorders
- Major depression
- Schizophrenia
- Attention Deficit Hyperactivity Disorder (ADHD)
- Mood and anxiety disorders
Additional areas
- Amyotrophic Lateral Sclerosis (ALS)
- Epilepsy and seizures
- Multiple Sclerosis
Reveal what matters most with our proprietary electronic cognitive and functional assessments
Designed by CNS experts to detect subtle, meaningful change while reducing participant and site burden. These include:
- Brief Assessment of Cognition (BAC): Electronic battery with improved sensitivity to impairment across key domains, enable earlier and more accurate detection of treatment effects.
- Virtual Reality Functional Capacity Assessment Tool (VRFCAT): Immersive, ecologically valid tasks measure real-world functioning, reflecting daily activities and increase the relevance of study outcomes.
- Schizophrenia Cognition Rating Scale (SCoRS): Interview-based measure sensitive to treatment effects and everyday impact.
- Simplified Negative and Positive Symptoms Interview (SNAPSI): Streamlined interview format providing valid PANSS ratings, reducing administrative time while maintaining scientific rigor and consistency. The PANSS Institute’s PANSS Rater certification is exclusively available in Virgil Academy.
Protect and elevate your CNS trials with expert guidance
Partner with our CNS scientists and operational leaders who specialize in endpoint protection, scale migration, rater enablement, and independent ratings.
Why sponsors choose Clario for CNS eCOA
Fit for purpose design from CNS-specific scientific and operational expertise.
Reduced variability and higher reliability through validated scales, expert training, independent review, and independent ratings.
Faster, simpler startup with an extensive library of pre-validated assessments and global translation coverage.
Seamless capture and smarter analytics, with gated eCOA access, a broad collection of eCOA data together with A/V recordings, and proprietary analytics streamlining the execution and oversight of our endpoint protection services.
References
- Rumerman, S., Brady, C., Negash, S., Seagal, I., & Opler, M. (2025, October). “From paper to precision: Improved MADRS scoring accuracy with eCOA implementation”. Poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, Amsterdam, Netherlands.
Ready to design a CNS eCOA solution that fits your study?
Let’s map your endpoints to the right science, training, and capabilities. Get started today.